| 摘要 |
A selective process is described for producing monohalogenated derivatives of 7-hydroxy coumarin wherein the halo substituent is at the desired position and the final product is free of other monohalogenated isomers. The resulting products, especially those wherein the halo substituent is at the 8 position, have valuable specific coronary vasodilating activity. |
